Symbols / ICCM Stock $4.37 -15.57% IceCure Medical Ltd
ICCM (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteIceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
Ratings
Current target
$4.37
Low
$30.00
High
$73.50
Mean
$44.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-14 | main | Maxim Group | Buy → Buy | $1 |
| 2025-10-07 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-08-15 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-21 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-07-02 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-03-20 | main | Alliance Global Partners | Buy → Buy | $3 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
- IceCure consolidates shares 30-to-1 in bid to keep Nasdaq listing - Stock Titan ue, 02 Jun 2026 12
- IceCure Medical (ICCM) Announces 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing - GuruFocus ue, 02 Jun 2026 18
- IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance ue, 12 May 2026 07
- IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - PR Newswire Wed, 13 May 2026 20
- IceCure Medical (NASDAQ: ICCM) implements 1-for-30 reverse share split for Nasdaq - Stock Titan ue, 02 Jun 2026 12
- IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance - Sahm ue, 02 Jun 2026 07
- Why Has IceCure Medical's Stock Price Collapsed - Kavout ue, 12 May 2026 07
- When Will IceCure Medical Ltd (NASDAQ:ICCM) Turn A Profit? - Yahoo Finance hu, 15 Jan 2026 08
- IceCure given until Nov. 9 to lift Nasdaq share price above $1 - Stock Titan Wed, 13 May 2026 07
- IceCure Medical (ICCM) CFO reports 400,000 RSUs equity grant - Stock Titan Mon, 18 May 2026 07
- Study: IceCure breast tumor freezing cuts costs 50% vs surgery - Stock Titan ue, 12 May 2026 07
- IceCure's breast tumor freezing tech sets sales record, eyes 7,130 patients - Stock Titan ue, 17 Mar 2026 07
- A frozen alternative to breast surgery gains U.S. authorization - Stock Titan Mon, 12 Jan 2026 08
- IceCure to release Q1 results before market, webcast at 11 a.m. EDT - Stock Titan Wed, 06 May 2026 07
- Freezing kidney tumors leaves 89% cancer-free at 4 years in IceCure study - Stock Titan ue, 19 May 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
3.38
+2.67%
|
3.29
+1.92%
|
3.23
+4.67%
|
3.08
|
| Operating Revenue |
|
3.38
+2.67%
|
3.29
+1.92%
|
3.23
+4.67%
|
3.08
|
| Cost Of Revenue |
|
2.15
+17.01%
|
1.84
-4.61%
|
1.93
+17.62%
|
1.64
|
| Reconciled Cost Of Revenue |
|
2.15
+17.01%
|
1.84
-4.61%
|
1.93
+17.62%
|
1.64
|
| Gross Profit |
|
1.23
-15.51%
|
1.45
+11.62%
|
1.30
-10.03%
|
1.45
|
| Operating Expense |
|
16.32
-4.82%
|
17.15
+1.61%
|
16.88
-7.19%
|
18.18
|
| Research And Development |
|
7.43
+4.75%
|
7.10
-14.23%
|
8.27
-9.32%
|
9.12
|
| Selling General And Administration |
|
8.89
-11.58%
|
10.05
+16.83%
|
8.60
-5.05%
|
9.06
|
| Selling And Marketing Expense |
|
1.04
-8.96%
|
1.14
-5.95%
|
1.21
+16.55%
|
1.04
|
| General And Administrative Expense |
|
7.85
-11.92%
|
8.91
+20.56%
|
7.39
-7.85%
|
8.02
|
| Salaries And Wages |
|
5.00
+17.24%
|
4.26
+3.35%
|
4.12
+6.84%
|
3.86
|
| Other Gand A |
|
2.85
-38.65%
|
4.65
+42.30%
|
3.27
-21.49%
|
4.16
|
| Total Expenses |
|
18.47
-2.71%
|
18.99
+0.97%
|
18.80
-5.14%
|
19.82
|
| Operating Income |
|
-15.09
+3.84%
|
-15.70
-0.77%
|
-15.58
+6.95%
|
-16.74
|
| Total Operating Income As Reported |
|
-15.09
+3.84%
|
-15.70
-0.77%
|
-15.58
+6.95%
|
-16.74
|
| EBITDA |
|
-14.80
+3.68%
|
-15.36
-0.73%
|
-15.25
+7.51%
|
-16.49
|
| Normalized EBITDA |
|
-14.80
+3.68%
|
-15.36
-0.73%
|
-15.25
+7.51%
|
-16.49
|
| Reconciled Depreciation |
|
0.29
-11.14%
|
0.33
+2.79%
|
0.32
+30.24%
|
0.25
|
| EBIT |
|
-15.09
+3.84%
|
-15.70
-0.77%
|
-15.58
+6.95%
|
-16.74
|
| Net Income |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Pretax Income |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Net Non Operating Interest Income Expense |
|
0.04
-90.21%
|
0.38
-59.09%
|
0.92
+486.61%
|
-0.24
|
| Net Interest Income |
|
0.04
-90.21%
|
0.38
-59.09%
|
0.92
+486.61%
|
-0.24
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Net Income From Continuing Operation Net Minority Interest |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Net Income From Continuing And Discontinued Operation |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Net Income Continuous Operations |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Normalized Income |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Net Income Common Stockholders |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Diluted EPS |
|
-7.20
+18.47%
|
-8.83
+8.01%
|
-9.60
+29.10%
|
-13.54
|
| Basic EPS |
|
-7.20
+18.47%
|
-8.83
+8.01%
|
-9.60
+29.10%
|
-13.54
|
| Basic Average Shares |
|
2.12
+22.62%
|
1.73
+13.61%
|
1.52
+20.97%
|
1.26
|
| Diluted Average Shares |
|
2.12
+22.62%
|
1.73
+13.61%
|
1.52
+20.97%
|
1.26
|
| Diluted NI Availto Com Stockholders |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Total Other Finance Cost |
|
-0.04
+90.21%
|
-0.38
+59.09%
|
-0.92
-486.61%
|
0.24
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
16.41
|
| Current Assets |
|
14.18
|
| Cash Cash Equivalents And Short Term Investments |
|
11.06
|
| Cash And Cash Equivalents |
|
10.53
|
| Other Short Term Investments |
|
0.53
|
| Receivables |
|
0.23
|
| Accounts Receivable |
|
0.10
|
| Gross Accounts Receivable |
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
| Other Receivables |
|
0.01
|
| Taxes Receivable |
|
0.11
|
| Inventory |
|
2.27
|
| Raw Materials |
|
1.39
|
| Work In Process |
|
0.32
|
| Finished Goods |
|
0.57
|
| Prepaid Assets |
|
0.62
|
| Restricted Cash |
|
0.00
|
| Total Non Current Assets |
|
2.23
|
| Net PPE |
|
2.19
|
| Gross PPE |
|
3.41
|
| Accumulated Depreciation |
|
-1.22
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.56
|
| Other Properties |
|
2.64
|
| Leases |
|
0.21
|
| Non Current Prepaid Assets |
|
—
|
| Other Non Current Assets |
|
0.03
|
| Total Liabilities Net Minority Interest |
|
4.25
|
| Current Liabilities |
|
3.87
|
| Payables And Accrued Expenses |
|
2.78
|
| Payables |
|
0.50
|
| Accounts Payable |
|
0.50
|
| Current Accrued Expenses |
|
2.28
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.22
|
| Current Capital Lease Obligation |
|
0.22
|
| Current Deferred Liabilities |
|
0.19
|
| Current Deferred Revenue |
|
0.19
|
| Total Non Current Liabilities Net Minority Interest |
|
0.38
|
| Long Term Debt And Capital Lease Obligation |
|
0.38
|
| Long Term Capital Lease Obligation |
|
0.38
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
12.16
|
| Common Stock Equity |
|
12.16
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
—
|
| Share Issued |
|
1.55
|
| Ordinary Shares Number |
|
1.55
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
102.22
|
| Retained Earnings |
|
-90.06
|
| Treasury Stock |
|
—
|
| Total Equity Gross Minority Interest |
|
12.16
|
| Total Capitalization |
|
12.16
|
| Working Capital |
|
10.31
|
| Invested Capital |
|
12.16
|
| Total Debt |
|
0.60
|
| Capital Lease Obligations |
|
0.60
|
| Net Tangible Assets |
|
12.16
|
| Tangible Book Value |
|
12.16
|
| Current Provisions |
|
0.68
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-14.57
-16.01%
|
-12.56
-0.10%
|
-12.55
+12.19%
|
-14.29
|
| Cash Flow From Continuing Operating Activities |
|
-14.57
-16.01%
|
-12.56
-0.10%
|
-12.55
+12.19%
|
-14.29
|
| Net Income From Continuing Operations |
|
-15.06
+1.70%
|
-15.32
-4.55%
|
-14.65
+13.70%
|
-16.98
|
| Depreciation Amortization Depletion |
|
0.29
-11.14%
|
0.33
+2.79%
|
0.32
+30.24%
|
0.25
|
| Depreciation |
|
0.29
-11.14%
|
0.33
+2.79%
|
0.32
+30.24%
|
0.25
|
| Depreciation And Amortization |
|
0.29
-11.14%
|
0.33
+2.79%
|
0.32
+30.24%
|
0.25
|
| Other Non Cash Items |
|
—
|
—
|
-0.03
|
—
|
| Stock Based Compensation |
|
1.37
+58.00%
|
0.87
-33.66%
|
1.31
-29.76%
|
1.86
|
| Operating Gains Losses |
|
-0.11
-392.31%
|
0.04
+256.00%
|
-0.03
-106.96%
|
0.36
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.11
-392.31%
|
0.04
+256.00%
|
-0.03
-106.96%
|
0.36
|
| Change In Working Capital |
|
-1.07
-170.69%
|
1.51
+189.67%
|
0.52
+144.39%
|
0.21
|
| Change In Receivables |
|
-0.11
+6.78%
|
-0.12
-372.00%
|
-0.03
-106.61%
|
0.38
|
| Changes In Account Receivables |
|
-0.11
+6.78%
|
-0.12
-372.00%
|
-0.03
-106.61%
|
0.38
|
| Change In Inventory |
|
-0.64
-321.95%
|
0.29
-50.69%
|
0.58
+164.52%
|
-0.90
|
| Change In Prepaid Assets |
|
0.23
+196.62%
|
-0.24
-147.78%
|
0.50
-52.76%
|
1.05
|
| Change In Payables And Accrued Expense |
|
-0.37
-150.55%
|
0.73
+444.34%
|
-0.21
-26.95%
|
-0.17
|
| Change In Payable |
|
-0.37
-150.55%
|
0.73
+444.34%
|
-0.21
-26.95%
|
-0.17
|
| Change In Account Payable |
|
-0.37
-150.55%
|
0.73
+444.34%
|
-0.21
-26.95%
|
-0.17
|
| Change In Other Working Capital |
|
-0.10
-112.83%
|
0.76
+641.84%
|
-0.14
|
—
|
| Change In Other Current Assets |
|
0.33
+20.66%
|
0.27
+48.90%
|
0.18
-25.71%
|
0.24
|
| Change In Other Current Liabilities |
|
-0.41
-126.92%
|
-0.18
+49.30%
|
-0.36
+7.95%
|
-0.39
|
| Investing Cash Flow |
|
-0.04
-108.07%
|
0.45
+165.20%
|
-0.68
+23.23%
|
-0.89
|
| Cash Flow From Continuing Investing Activities |
|
-0.04
-108.07%
|
0.45
+165.20%
|
-0.68
+23.23%
|
-0.89
|
| Net PPE Purchase And Sale |
|
-0.04
+49.30%
|
-0.07
+85.21%
|
-0.48
+46.13%
|
-0.89
|
| Purchase Of PPE |
|
-0.04
+49.30%
|
-0.07
+85.21%
|
-0.48
+46.13%
|
-0.89
|
| Capital Expenditure |
|
-0.04
+49.30%
|
-0.07
+85.21%
|
-0.48
+46.13%
|
-0.89
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
0.53
+205.80%
|
-0.50
|
0.00
|
| Purchase Of Investment |
|
-5.00
-264.17%
|
-1.37
-174.60%
|
-0.50
|
0.00
|
| Sale Of Investment |
|
5.00
+162.88%
|
1.90
|
0.00
|
0.00
|
| Net Other Investing Changes |
|
—
|
-0.01
-104.05%
|
0.30
|
—
|
| Financing Cash Flow |
|
15.83
+72.35%
|
9.19
+10968.67%
|
0.08
-99.39%
|
13.58
|
| Cash Flow From Continuing Financing Activities |
|
15.83
+72.35%
|
9.19
+10968.67%
|
0.08
-99.39%
|
13.58
|
| Net Issuance Payments Of Debt |
|
0.00
|
0.00
|
0.00
|
—
|
| Issuance Of Debt |
|
2.00
|
0.00
|
0.00
|
—
|
| Repayment Of Debt |
|
-2.00
|
0.00
|
0.00
|
—
|
| Long Term Debt Issuance |
|
2.00
|
0.00
|
0.00
|
—
|
| Long Term Debt Payments |
|
-2.00
|
0.00
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
0.00
|
0.00
|
0.00
|
—
|
| Net Common Stock Issuance |
|
15.54
+69.14%
|
9.19
+10968.67%
|
0.08
-99.39%
|
13.57
|
| Proceeds From Stock Option Exercised |
|
0.29
|
0.00
|
0.00
-100.00%
|
0.00
|
| Changes In Cash |
|
1.22
+141.77%
|
-2.93
+77.72%
|
-13.15
-718.87%
|
-1.61
|
| Effect Of Exchange Rate Changes |
|
0.11
+379.49%
|
-0.04
-256.00%
|
0.03
+107.02%
|
-0.36
|
| Beginning Cash Position |
|
7.56
-28.19%
|
10.53
-55.48%
|
23.66
-7.66%
|
25.62
|
| End Cash Position |
|
8.90
+17.62%
|
7.56
-28.19%
|
10.53
-55.48%
|
23.66
|
| Free Cash Flow |
|
-14.61
-15.64%
|
-12.63
+3.04%
|
-13.03
+14.18%
|
-15.18
|
| Common Stock Issuance |
|
15.54
+69.14%
|
9.19
+10968.67%
|
0.08
-99.39%
|
13.57
|
| Issuance Of Capital Stock |
|
15.54
+69.14%
|
9.19
+10968.67%
|
0.08
-99.39%
|
13.57
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|